A team at AIBN has developed a world-first assay that rapidly measures interactions between tiny particles in the bloodstream - a crucial step in understanding how diseases like cancer develop and spread.
The distance between a researcher at the lab bench and a patient in a hospital chair is vast, with one immersed in test tubes and protocols, and the other navigating uncertainty, hope, and side effects.
Every 12 minutes, one Australian dies of cardiovascular disease, accounting for 40,000+ annual deaths at a cost of $11.8B/year. Want to help us develop treatments for cardiovascular disease, the leading cause of death worldwide
AIBN Associate Professor Joy Wolfram believes decoding a cellular messaging system will give them the upper hand against a particularly deadly type of breast cancer.
Liposomes are self-assembling lipid-based nanoparticles that enclose an aqueous core. An advantage of liposomes is versatility in terms of efficient loading of both hydrophilic and hydrophobic therapeutics.
Associate Professor Joy Wolfram leads a nanomedicine and extracellular vesicle research program with the goal of developing innovative approaches that bring the next generation of treatments and diagnostics directly to the clinic.
